SCLC

[Cell Reports] Researchers showed that the expression of TIAM1, an activator of the small GTPase RAC1, was associated with a neuroendocrine gene program.

[BeyondSpring, Inc.] BeyondSpring announced the first patient has been treated in an investigator-initiated, open-label Phase II study with lead asset plinabulin in combination with nivolumab + ipilimumab in patients with 3rd line recurrent small-cell lung cancer who failed checkpoint inhibitors and platinum-based chemotherapy.

[Modern Pathology] The author summarizes key recent developments relevant to the pathologic diagnosis of lung neuroendocrine neoplasms, including carcinoids, small cell lung carcinoma, and large cell neuroendocrine carcinoma.

[Cancer Cell] Scientists sequenced 155,098 transcriptomes from 21 human biospecimens, including 54,523 small cell lung cancer (SCLC) transcriptomes. They observed greater tumor diversity in SCLC than lung adenocarcinoma, driven by canonical, intermediate, and admixed subtypes.

[Proceedings of the National Academy of Sciences of the United States of America] The MYC axis is disrupted in cancer, predominantly through activation of the MYC family oncogenes but also through inactivation of the MYC partner MAX or of the MAX partner MGA. Researchers demonstrated that MAX-deficient small-cell lung cancer cells have either ASCL1 or NEUROD1 or combined characteristics.

[Medical Oncology] Scientists determined the effect of lncRNA HIF1A-AS2 on autophagy-associated drug resistance in SCLC. The expression of HIF1A-AS2 was silenced by siRNA in doxorubicin-sensitive H69 and doxorubicin-resistant H69AR cells.